ArticleAmerican journal of cancer research2025
Enhanced prognostic stratification in early-stage epithelial ovarian cancer: multi-histological analysis of neutrophil-to-lymphocyte ratio with particular emphasis on clear cell histology.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Asian populations, early-stage ovarian cancers account for approximately half of cases, substantially exceeding proportions observed in Western cohorts, with clear cell carcinoma (CCC) and endometrioid carcinoma (EMC) demonstrating markedly higher prevalence in Asian women. The tumor immune microenvironment critically influences oncological progression, and systemic inflammatory biomarkers can serve as surrogates of host immunological responses. This study evaluated the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), an established index of systemic inflammation and immune dysregulation, across histologic subtypes in early-stage epithelial ovarian cancer. We retrospectively analyzed patients with FIGO stage I-II epithelial ovarian cancer diagnosed between 2011 and 2018. Pretreatment NLR was calculated to reflect the balance between neutrophil-driven inflammation and lymphocyte-mediated immunity. Among 217 enrolled patients, CCC (28.1%) and EMC (34.6%) constituted the predominant histotypes, consistent with Asian demographic patterns. In univariable analyses, elevated NLR and advanced stage significantly correlated with diminished progression-free survival (HR 5.04, P<0.001; HR 3.81, P<0.001) and overall survival (HR 4.54, P=0.013; HR 3.91, P=0.003). In multivariable models, NLR remained an independent prognostic factor for both endpoints (PFS: HR 5.38, P=0.001; OS: HR 4.27, P=0.048). Histology-stratified analyses revealed distinctive immunological signatures, with elevated NLR in CCC patients exhibiting exceptionally strong prognostic value (univariable PFS: HR 8.14, P=0.001; OS: HR 22.42, P=0.005; multivariable PFS: HR 8.00, P=0.007; OS: HR 32.43, P=0.025), providing information beyond FIGO stage. Conversely, NLR demonstrated no prognostic relevance in EMC patients, indicating heterogeneous immune microenvironments across histological variants. Elevated pre-treatment NLR independently predicts adverse outcomes in early-stage epithelial ovarian cancer, with particularly pronounced prognostic utility in CCC. These findings may be especially relevant in Asian populations, in which CCC is more common, and could inform personalized risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.